- Home
- RRC vs LEGN Comparison
RRC vs LEGN Comparison
Compare RRC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRC
- LEGN
- Stock Information
- Founded
- RRC 1976
- LEGN 2014
- Country
- RRC United States
- LEGN United States
- Employees
- RRC N/A
- LEGN N/A
- Industry
- RRC Oil & Gas Production
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- RRC Energy
- LEGN Health Care
- Exchange
- RRC Nasdaq
- LEGN Nasdaq
- Market Cap
- RRC 8.0B
- LEGN 7.0B
- IPO Year
- RRC N/A
- LEGN 2020
- Fundamental
- Price
- RRC $39.51
- LEGN $28.91
- Analyst Decision
- RRC Hold
- LEGN Strong Buy
- Analyst Count
- RRC 18
- LEGN 13
- Target Price
- RRC $42.53
- LEGN $75.67
- AVG Volume (30 Days)
- RRC 2.6M
- LEGN 1.7M
- Earning Date
- RRC 07-22-2025
- LEGN 05-13-2025
- Dividend Yield
- RRC 0.91%
- LEGN N/A
- EPS Growth
- RRC N/A
- LEGN N/A
- EPS
- RRC 1.11
- LEGN N/A
- Revenue
- RRC $2,610,836,000.00
- LEGN $728,303,000.00
- Revenue This Year
- RRC $30.49
- LEGN $64.21
- Revenue Next Year
- RRC $11.49
- LEGN $53.69
- P/E Ratio
- RRC $35.37
- LEGN N/A
- Revenue Growth
- RRC 12.00
- LEGN 112.46
- 52 Week Low
- RRC $27.29
- LEGN $27.34
- 52 Week High
- RRC $41.95
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- RRC 61.99
- LEGN 39.95
- Support Level
- RRC $38.74
- LEGN $28.14
- Resistance Level
- RRC $40.54
- LEGN $31.12
- Average True Range (ATR)
- RRC 0.93
- LEGN 1.87
- MACD
- RRC 0.19
- LEGN -0.16
- Stochastic Oscillator
- RRC 76.84
- LEGN 25.95
About RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.